Dianthus Therapeutics, Inc.

NasdaqCM:DNTH Stock Report

Market Cap: US$5.2b

Dianthus Therapeutics Management

Management criteria checks 2/4

Dianthus Therapeutics' CEO is Marino Garcia, appointed in Nov 2021, has a tenure of 4.67 years. total yearly compensation is $10.61M, comprised of 5.9% salary and 94.1% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $6.16M. The average tenure of the management team and the board of directors is 3 years and 2.8 years respectively.

Key information

Marino Garcia

Chief executive officer

US$10.6m

Total compensation

CEO salary percentage5.94%
CEO tenure4.7yrs
CEO ownership0.1%
Management average tenure3yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

Analysis Article • Jun 17

Dianthus Therapeutics (DNTH) Stock After CAPTIVATE Results Looks Fairly Valued

Dianthus Therapeutics (DNTH) drew fresh attention after reporting positive midstage results from its CAPTIVATE Phase 3 trial in chronic inflammatory demyelinating polyneuropathy, highlighting a high confirmed responder rate along with a favorable safety profile. See our latest analysis for Dianthus Therapeutics. The CAPTIVATE data arrived after a strong run in Dianthus Therapeutics, with the share price at $78.88 and a year to date share price return of 98.79%. Short term momentum has cooled,...
Seeking Alpha • May 30

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

Summary Dianthus Therapeutics is positioned as a category-expanding biotech, leveraging convenience and safety to address autoimmune neuromuscular and rheumatology markets. DNTH boasts a robust balance sheet with over $1 billion in cash and investments, ensuring operational runway through 2030 and strategic independence post-positive clinical data. Claseprubart’s promising efficacy and safety in gMG, CIDP, and MMN, alongside the DNTH212 rheumatology franchise, underpin a multi-pronged growth thesis with major catalysts in late 2026. Valuation is driven by optionality from a well-funded pipeline, but key risks remain in Phase 3 trial translation and competitive differentiation against established players. Read the full article on Seeking Alpha
Analysis Article • Jul 10

We Think Dianthus Therapeutics (NASDAQ:DNTH) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Compensation Analysis

How has Marino Garcia's remuneration changed compared to Dianthus Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$174m

Dec 31 2025US$11mUS$630k

-US$162m

Sep 30 2025n/an/a

-US$126m

Jun 30 2025n/an/a

-US$115m

Mar 31 2025n/an/a

-US$101m

Dec 31 2024US$9mUS$600k

-US$85m

Sep 30 2024n/an/a

-US$67m

Jun 30 2024n/an/a

-US$57m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$496kUS$175k

-US$44m

Compensation vs Market: Marino's total compensation ($USD10.61M) is about average for companies of similar size in the US market ($USD8.35M).

Compensation vs Earnings: Marino's compensation has increased whilst the company is unprofitable.

CEO

Marino Garcia (60 yo)

4.7yrs
Tenure
US$10,614,702
Compensation

Mr. Marino Garcia, M.B.A., serves as President and Chief Executive Officer at Dianthus Therapeutics, Inc, since November 2021 and its Director since September 2023 also served as its Secretary until 2024....

Leadership Team

NamePositionTenureCompensationOwnership
Marino Garcia
President4.7yrsUS$10.61m0.12%
$ 6.2m
Ryan Savitz
Executive VP2.8yrsUS$5.07mno data
Simrat Randhawa
Executive VP and Head of R&D4.2yrsUS$5.22m0.0073%
$ 377.5k
Edward Carr
Senior VP & Chief Accounting Officer2.8yrsno datano data
Judson Taylor
Senior VP & Head of Technical Operationsno datano datano data
Jennifer Ruff
VP and Head of Investor Relations & Corporate Affairs2.7yrsno datano data
Adam Veness
Senior VP3.1yrsno datano data
Kristina Maximenko
Chief People Officerno datano datano data
Rashieda Gluck
Head of Clinical Development Operationsno datano datano data
Scott Nogi
Head of Business Operationsno datano datano data
Debra Segal
Head of Regulatory Affairsno datano datano data
Polly Hanff
Head of Qualityno datano datano data
3.0yrs
Average Tenure
56yo
Average Age

Experienced Management: DNTH's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marino Garcia
President2.8yrsUS$10.61m0.12%
$ 6.2m
Alison Lawton
Independent Chairman of the Board5.6yrsUS$259.79k0%
$ 0
Sujay Kango
Independent Director1.3yrsUS$418.86k0%
$ 0
Anne McGeorge
Independent Director7.1yrsUS$232.38k0%
$ 0
Jonathan Violin
Independent Director7yrsUS$217.48k0%
$ 0
Steven Romano
Independent Director1.8yrsUS$225.65k0%
$ 0
Paula Soteropoulos
Independent Director2.8yrsUS$231.79k0%
$ 0
Simon Read
Independent Director1.2yrsUS$382.31k0%
$ 0
2.8yrs
Average Tenure
61yo
Average Age

Experienced Board: DNTH's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 19:07
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dianthus Therapeutics, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Colleen KusyBaird
null nullBaird